Drug intelligence / Profile preview

methotrexate + maraviroc

Development stage: Discontinued
Lead developer: Pfizer
Modality: Small Molecules
Administration: Oral

Overview

A combination therapy consisting of methotrexate, a folate antagonist with anti-inflammatory properties, and maraviroc, a CCR5 antagonist. This combination was investigated for the treatment of rheumatoid arthritis, with maraviroc added to background methotrexate therapy. While the combination showed no drug-drug interactions and was generally well-tolerated, clinical trials demonstrated that adding maraviroc to methotrexate failed to improve signs and symptoms in patients with active rheumatoid arthritis.

Brand names: SelzentryRheumatrexTrexallOtrexup

Targets

DHFR (Dihydrofolate reductase)ATIC (Aminoimidazole carboxamide ribonucleotide transformylase)CCR5 (C-C chemokine receptor type 5)TS (Thymidylate synthase)

Beyond the preview

Go deeper on methotrexate + maraviroc.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on methotrexate + maraviroc.

Explore the full profile